Stephen M Pastores1, Debra A Goldman2, David J Shaz1, Natalie Kostelecky1, Ryan J Daley3, Tim J Peterson3, Kay See Tan2, Neil A Halpern1. 1. Critical Care Center, Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York.
Abstract
BACKGROUND: The objective of this study was to evaluate the short-term and long-term outcomes of adult patients with hematologic malignancies who received chemotherapy in the intensive care unit (ICU). METHODS: This was a retrospective, single-center study comparing the outcomes of patients with hematologic malignancies who received chemotherapy in the ICU with a matched cohort of ICU patients who did not receive chemotherapy. Conditional logistic regression and shared-frailty Cox regression were used to assess short-term (ICU and hospital) mortality and death by 12 months after hospital discharge, respectively. RESULTS: One hundred eighty-one patients with hematologic malignancies received chemotherapy in the ICU. The ICU and hospital mortality rates were 25% and 42% for chemotherapy patients and 22% and 33% for non-chemotherapy patients, respectively. Higher severity of illness scores on ICU admission were significantly associated with higher ICU mortality (odds ratio, 1.07; P < .001) and hospital mortality (odds ratio, 1.05; P ≤ .001). Six-month and 12-month survival estimates posthospital discharge were 58% and 50%, respectively. Compared with the matched cohort of patients who did not receive chemotherapy, those who did receive chemotherapy had a significantly longer length of stay in the ICU (median, 6 vs 3 days; P < .001) and in the hospital (median, 22 vs 14 days; P = .024). In multivariable analysis, the patients who received chemotherapy in the ICU had a trend toward a higher risk of dying by 12 months (hazard ratio, 1.45; P = .08). CONCLUSIONS: Short-term mortality was similar among patients with hematologic malignancies who did and did not receive chemotherapy in the ICU, although patients who received chemotherapy had increased resource utilization. These results may inform ICU triage and goals-of-care discussions with patients and their families regarding outcomes after receiving chemotherapy in the ICU. Cancer 2018;124:3025-36.
BACKGROUND: The objective of this study was to evaluate the short-term and long-term outcomes of adult patients with hematologic malignancies who received chemotherapy in the intensive care unit (ICU). METHODS: This was a retrospective, single-center study comparing the outcomes of patients with hematologic malignancies who received chemotherapy in the ICU with a matched cohort of ICU patients who did not receive chemotherapy. Conditional logistic regression and shared-frailty Cox regression were used to assess short-term (ICU and hospital) mortality and death by 12 months after hospital discharge, respectively. RESULTS: One hundred eighty-one patients with hematologic malignancies received chemotherapy in the ICU. The ICU and hospital mortality rates were 25% and 42% for chemotherapy patients and 22% and 33% for non-chemotherapy patients, respectively. Higher severity of illness scores on ICU admission were significantly associated with higher ICU mortality (odds ratio, 1.07; P < .001) and hospital mortality (odds ratio, 1.05; P ≤ .001). Six-month and 12-month survival estimates posthospital discharge were 58% and 50%, respectively. Compared with the matched cohort of patients who did not receive chemotherapy, those who did receive chemotherapy had a significantly longer length of stay in the ICU (median, 6 vs 3 days; P < .001) and in the hospital (median, 22 vs 14 days; P = .024). In multivariable analysis, the patients who received chemotherapy in the ICU had a trend toward a higher risk of dying by 12 months (hazard ratio, 1.45; P = .08). CONCLUSIONS: Short-term mortality was similar among patients with hematologic malignancies who did and did not receive chemotherapy in the ICU, although patients who received chemotherapy had increased resource utilization. These results may inform ICU triage and goals-of-care discussions with patients and their families regarding outcomes after receiving chemotherapy in the ICU. Cancer 2018;124:3025-36.
Authors: Dominique D Benoit; Pieter O Depuydt; Koenraad H Vandewoude; Fritz C Offner; Tom Boterberg; Carole A De Cock; Lucien A Noens; Ann M Janssens; Johan M Decruyenaere Journal: Intensive Care Med Date: 2005-11-25 Impact factor: 17.440
Authors: Peter Schellongowski; Michael Benesch; Thomas Lang; Friederike Traunmüller; Christian Zauner; Klaus Laczika; Gottfried J Locker; Michael Frass; Thomas Staudinger Journal: Intensive Care Med Date: 2003-11-04 Impact factor: 17.440
Authors: Michael von Bergwelt-Baildon; Michael J Hallek; Alexander A Shimabukuro-Vornhagen; Matthias Kochanek Journal: BMC Cancer Date: 2010-11-08 Impact factor: 4.430
Authors: Dominique D Benoit; Koenraad H Vandewoude; Johan M Decruyenaere; Eric A Hoste; Francis A Colardyn Journal: Crit Care Med Date: 2003-01 Impact factor: 7.598
Authors: G Maschmeyer; F-L Bertschat; K T Moesta; E Häusler; T K Held; M Nolte; K-J Osterziel; V Papstein; M Peters; G Reich; M Schmutzler; O Sezer; M Stula; H Wauer; T Wörtz; M Wischnewsky; P Hohenberger Journal: Eur J Cancer Date: 2003-04 Impact factor: 9.162
Authors: David J Shaz; Stephen M Pastores; Debra A Goldman; Natalie Kostelecky; Richard F Tizon; Kay See Tan; Neil A Halpern Journal: Support Care Cancer Date: 2019-12-14 Impact factor: 3.603
Authors: Benjamin Gershkovich; Shannon M Fernando; Brent Herritt; Lana A Castellucci; Bram Rochwerg; Laveena Munshi; Sangeeta Mehta; Andrew J E Seely; Daniel I McIsaac; Alexandre Tran; Peter M Reardon; Peter Tanuseputro; Kwadwo Kyeremanteng Journal: Crit Care Date: 2019-08-27 Impact factor: 9.097
Authors: Frank Daniel Martos-Benítez; Caridad de Dios Soler-Morejón; Karla Ximena Lara-Ponce; Versis Orama-Requejo; Dailé Burgos-Aragüez; Hilev Larrondo-Muguercia; Rahim W Lespoir Journal: World J Clin Oncol Date: 2020-10-24